Anormal Uterin Kanamalı Hastalarda Nötrofil/Lenfosit Oranı ve Platelet/Lenfosit Oranı Endometrial Hiperplazi ve Progestoron Tedavisi ile İlişkili midir?

Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios Associated With Endometrial Hyperplasia and Progesterone Treatment in Patients With Abnormal Uterine Bleeding?

Dilek ÜNAL, İpek MÜDERRİS, Başak CINĞILLIOĞLU, Hüseyin AKSOY, Ülkü AKSOY, Sezin ÖZYURT, Gülender TEKİN TAŞ, Gökhan AÇMAZ

Özet

Aim: An easy, reproducible, non-invasive and simple marker is needed to distinguish endometrial hyperplasia andnormal pathologic results. We aimed to clarify association among neutrophil-to-lymphocyte ratio (NLR), plateletto-lymphocyte ratio (PLR), endometrial hyperplasia and normal pathologic results in patients with abnormal uterinebleeding. Material and Methods: Patients (n=80) who were administered with abnormal uterine bleeding and the presence ofendometrial cells on cervical cytology or thick endometrium were investigated. The study constituted of two groupsaccording to pathologic diagnosis of volunteers. Hyperplasia group included endometrial precancerous lesions likesimple hyperplasia without atipia (n=40), normal pathology group included patients who had normal pathologicresults (n=40). Additionally we divided endometrial hyperplasia patients into two groups according to progesteronetreatment response. Group 1 (women who treated with progesterone and second curettage result was defined as be- nign lesions group n=32), group 2 (women who treated with progesterone and second curettage result was definedas precancerous lesion EH n=8) then subgroup comparisons were made between two groups. Blood samples wereobtained just before curettage procedure and the NLR was defined as the absolute neutrophil count divided by theabsolute lymphocyte count; similarly, PLR was defined as the absolute platelet count divided by the absolute lym- phocyte count. Results: Mean age was 46.1 ± 6.1 years in hyperplasia group and 45.6±4.0 years in control group. Median neutrophilto lymphocyte ratio and platelet to lymphocyte ratio were 2.01 (0.95-5.75) and 1.81 (0.94 4.01), 147 ± 59 and 128± 48 respectively. There were no significant differences between groups for hemoglobin, hematocrit, anemia, WBC,NLR, PLR and platelet values. Additionally these parameters did not differ after three months progesterone treatment. Conclusions: As far as we know, there have been no previous studies that have investigated these parameters forevaluating progesterone treatment response in patients with hyperplasia and distinguishing endometrial hyperplasiaand pathologically normal patients. We did not find any significant differences between both groups. By using mul- tiple inflammation parameters, discrimination may not be possible between endometrial precancerous lesions andpathologically normal patients.

Abstract

Aim: An easy, reproducible, non-invasive and simple marker is needed to distinguish endometrial hyperplasia andnormal pathologic results. We aimed to clarify association among neutrophil-to-lymphocyte ratio (NLR), platelet- to-lymphocyte ratio (PLR), endometrial hyperplasia and normal pathologic results in patients with abnormal uterinebleeding. Material and Methods: Patients (n=80) who were administered with abnormal uterine bleeding and the presence ofendometrial cells on cervical cytology or thick endometrium were investigated. The study constituted of two groupsaccording to pathologic diagnosis of volunteers. Hyperplasia group included endometrial precancerous lesions likesimple hyperplasia without atipia (n=40), normal pathology group included patients who had normal pathologicresults (n=40). Additionally we divided endometrial hyperplasia patients into two groups according to progesteronetreatment response. Group 1 (women who treated with progesterone and second curettage result was defined as be- nign lesions group n=32), group 2 (women who treated with progesterone and second curettage result was definedas precancerous lesion EH n=8) then subgroup comparisons were made between two groups. Blood samples wereobtained just before curettage procedure and the NLR was defined as the absolute neutrophil count divided by theabsolute lymphocyte count; similarly, PLR was defined as the absolute platelet count divided by the absolute lym- phocyte count. Results: Mean age was 46.1 ± 6.1 years in hyperplasia group and 45.6±4.0 years in control group. Median neutrophilto lymphocyte ratio and platelet to lymphocyte ratio were 2.01 (0.95-5.75) and 1.81 (0.94 4.01), 147 ± 59 and 128± 48 respectively. There were no significant differences between groups for hemoglobin, hematocrit, anemia, WBC,NLR, PLR and platelet values. Additionally these parameters did not differ after three months progesterone treatment. Conclusions: As far as we know, there have been no previous studies that have investigated these parameters forevaluating progesterone treatment response in patients with hyperplasia and distinguishing endometrial hyperplasiaand pathologically normal patients. We did not find any significant differences between both groups. By using mul- tiple inflammation parameters, discrimination may not be possible between endometrial precancerous lesions and pathologically normal patients.